Alexandraki Alexia, Papageorgiou Elisavet, Zacharia Marina, Keramida Kalliopi, Papakonstantinou Andri, Cipolla Carlo M, Tsekoura Dorothea, Naka Katerina, Mazzocco Ketti, Mauri Davide, Tsiknakis Manolis, Manikis Georgios C, Marias Kostas, Marcou Yiola, Kakouri Eleni, Konstantinou Ifigenia, Daniel Maria, Galazi Myria, Kampouroglou Effrosyni, Ribnikar Domen, Brown Cameron, Karanasiou Georgia, Antoniades Athos, Fotiadis Dimitrios, Filippatos Gerasimos, Constantinidou Anastasia
A.G. Leventis Clinical Trials Unit, Bank of Cyprus Oncology Centre, 32 Acropoleos Avenue, Nicosia 2006, Cyprus.
2nd Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Cancers (Basel). 2023 Jun 22;15(13):3290. doi: 10.3390/cancers15133290.
Cardiotoxicity induced by breast cancer therapies is a potentially serious complication associated with the use of various breast cancer therapies. Prediction and better management of cardiotoxicity in patients receiving chemotherapy is of critical importance. However, the management of cancer therapy-related cardiac dysfunction (CTRCD) lacks clinical evidence and is based on limited clinical studies.
To provide an overview of existing and potentially novel biomarkers that possess a promising predictive value for the early and late onset of CTRCD in the clinical setting.
A systematic review of published studies searching for promising biomarkers for the prediction of CTRCD in patients with breast cancer was undertaken according to PRISMA guidelines. A search strategy was performed using PubMed, Google Scholar, and Scopus for the period 2013-2023. All subjects were >18 years old, diagnosed with breast cancer, and received breast cancer therapies.
The most promising biomarkers that can be used for the development of an alternative risk cardiac stratification plan for the prediction and/or early detection of CTRCD in patients with breast cancer were identified.
We highlighted the new insights associated with the use of currently available biomarkers as a standard of care for the management of CTRCD and identified potentially novel clinical biomarkers that could be further investigated as promising predictors of CTRCD.
乳腺癌治疗引起的心脏毒性是与多种乳腺癌治疗方法使用相关的潜在严重并发症。对接受化疗患者的心脏毒性进行预测和更好的管理至关重要。然而，癌症治疗相关心脏功能障碍（CTRCD）的管理缺乏临床证据，且基于有限的临床研究。
概述在临床环境中对CTRCD的早期和晚期发病具有潜在预测价值的现有及可能的新型生物标志物。
根据PRISMA指南，对已发表的寻找乳腺癌患者CTRCD预测有前景生物标志物的研究进行系统综述。在2013年至2023年期间，使用PubMed、谷歌学术和Scopus进行检索策略。所有受试者年龄>18岁，诊断为乳腺癌，并接受乳腺癌治疗。
确定了最有前景的生物标志物，可用于制定替代风险心脏分层计划，以预测和/或早期检测乳腺癌患者的CTRCD。
我们强调了与使用当前可用生物标志物作为CTRCD管理的护理标准相关的新见解，并确定了可能的新型临床生物标志物，可作为CTRCD有前景的预测指标进行进一步研究。
